Outlaws the sale and use of organophosphate pesticides and mandates that the EPA cancel the registration of organophosphate pesticides from the Federal Insecticide, Fungicide, and Rodenticide Act.

Evaluates the reliability of previous research that compared the effectiveness of inhalation versus instillation of potentially carcinogenic nanoparticles at causing lung inflammation in rats.

Amends the Controlled Substances Act to require the Drug Enforcement Administration to provide more detailed reports on patterns of opioids sales to distributors and manufacturers to help monitor and curtail suspicious or illegal opioid orders.

Directs the Federal Government to protect the United States from biological threats.

Supports the United States’ leadership in the research and development of quantum science and technology.

Expresses the concern of Congress about whether future and current physicians are prepared to treat pain and prescribe opiates properly, and discusses the need to improve medical training to curtail the opioid epidemic.

Provides review of scientific literature on toxicological effects of exposure to silver nanomaterials, assessment of the potential health risks of occupational exposure to silver nanomaterials, and recommended exposure limits for silver nanomaterials.

Application for a patent for photoactivatable, lipid-based nanoparticles that can deliver anti-cancer and other drugs.

Establishes an evidence-based guideline for diagnosing and treating pediatric mild traumatic brain injury.

Sets goal for California's electric power sector to be 100% carbon-free by 2045

Addresses the shortage of mental health providers of the Department of Defense and develops a program to monitor prescriptions related to post-traumatic stress disorder.

Requires prominent labeling of drugs with an increased risk of suicide or depression.